A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
← catalyst calendarNCT06286046 · readout ≤ 284 d
Sponsored by Agios Pharmaceuticals, Inc. (industry) · AGIO — their whole pipeline →.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Withdrawn prior to study start per sponsor decision. No patients were enrolled.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Mar 2026 | estimated | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Nephropathy
Intervention
- Drug: Mitapivat — also filed as AG-348, Mitapivat sulfate, AG-348 sulfate hydrate
Primary outcome
what the primary-completion date above is the date OFPublications
- PMID 40569673 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AGIO's whole pipeline · Catalyst calendar · Every registered study · What changed